Viewing Study NCT01964534

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2026-03-13 @ 12:26 PM
Study NCT ID: NCT01964534
Status: UNKNOWN
Last Update Posted: 2017-01-31
First Post: 2013-10-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic View
None Pancreatic View
None Cancer View
None Pancreas View
None GERCOR View
None Gemcitabine View
None LV5FU2 View
None ABI-007 View
None PACLITAXEL ALBUMIN-BOUND PARTICLES View